Background: It is well known that there is considerable inter-observer variability in assessment of the pathological parameters that are used to select node-negative breast cancer patients for adjuvant systemic treatment. There are only limited data available as to in how many patients this leads to differences in treatment decisions.
introduction
In breast cancer, prognostic factors are used to identify patients who are at relatively high risk of developing distant metastases because these patients will potentially benefit most from adjuvant systemic treatment (e.g. chemotherapy, endocrine treatment and targeted therapy); predictive factors are used to select the optimal type of treatment. Currently used prognostic and predictive factors in breast cancer include age, tumour diameter, lymph node status, histologic grade, estrogen receptor (ER) status, progesterone receptor (PgR) status and HER2 status [1] . For decision making on adjuvant systemic treatment, most treatment guidelines advice adjuvant systemic treatment of patients with lymph node metastases; for lymph node-negative breast cancer patients, various algorithms based on age, tumour diameter and histologic grade are used [1] . Several clinicopathological guidelines for adjuvant systemic treatment have been developed on the basis of these factors [e.g. St Gallen guidelines, Adjuvant! Online and Nottingham Prognostic Index (NPI)] [2] [3] [4] [5] [6] [7] [8] [9] [10] . With the exception of age, these factors are determined by pathological examination of the breast cancer specimen. Several studies have shown considerable inter-observer variation in the assessment of these factors between pathologists [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . Lack of reproducibility and reliability of pathological examination and laboratory assays affects clinicopathological risk assessment and potentially adjuvant systemic treatment advice and decision making and could therefore affect patient outcome.
Concordance between pathologists in assessing grade was found to range from 50% to 85% [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . In general, these studies concluded that despite being subject to considerable inter-observer variation, which can be decreased by using standardised protocols, grade was a valuable prognostic indicator.
The most important predictive factors that are used for treatment decision making in breast cancer are ER status and HER2 status. Also for these predictive factors, considerable inter-observer variation for the assessment results has been observed ranging from 11% to 28% [24] [25] [26] . In part, these differences are due to methodological differences in the staining technique used, and in part, they are due to differences in the interpretation of the staining results [22, 23] . Intra-laboratory and inter-laboratory variation in ER assay methodology and reporting of results has varied considerably since the ER test was first introduced in clinical practice in the 1970s [27] .
None of the studies investigating the inter-observer variation of prognostic and predictive markers have directly evaluated the impact on clinicopathological risk assessment and patient selection for adjuvant systemic treatment. Therefore, the aim of the present study was to assess the effect of inter-observer variation in pathological examination of node-negative breast cancer on the selection of patients for adjuvant systemic treatment using various clinicopathological guidelines (i.e. national Dutch guidelines formulated by the Dutch Institute for Healthcare Improvement (CBO guidelines), St Gallen guidelines, NPI and Adjuvant! Online).
methods study design
For this retrospective study, the clinical and pathological data from two consecutive patient series diagnosed from 1996 to 2006 were analysed. The first series consisted of 123 patients of a validation study of the 70-gene prognosis signature carried out by Bueno-de-Mesquita et al. [28] , hereafter referred to as the 'validation series'. The second series is a subset of 585 patients from the previously reported MicroarRAy PrognoSTics in Breast CancER (RASTER) study (ISRCTN71917916), hereafter referred to as 'the RASTER series' [29] . Clinical and pathological data retrieved from the patient files for the 14 patients for whom tumour samples could not be retrieved did not significantly differ from the 694 patients analysed for this study (data not shown). This study was part of the RASTER study. Institutional approval for the RASTER study was obtained from the Institutional Review Board of The Netherlands Cancer Institute [29] . patients validation series. The validation series consisted of a consecutive series of patients <55 years of age who had received adequate local therapy for earlystage breast cancer, defined as node negative, tumour diameter <5 cm (pT1-2). Patients in this series were treated at two Dutch hospitals, The Netherlands Cancer Institute (Amsterdam) and the Reinier de Graaf Hospital (RdGG; Delft) from 1996 to 1999. Details on the validation series have been reported previously [28] . Paraffin-embedded tumour blocks with a representative tumour sample could not be retrieved in 1 of 123 (0.8%) patients in this series.
RASTER series. Details on the patient series of the RASTER study (ISRCTN71917916) have been reported previously [29] . For this study, only patients who were eligible according to inclusion and exclusion criteria from the RASTER study were included in the analysis (N = 585). Patients were diagnosed with node-negative breast cancer from 2004 to 2006 at 16 Dutch hospitals. Paraffin-embedded tumour blocks with a representative tumour sample could not be retrieved in 13 of 585 (2%) patients in this series.
local pathological examination
Hematoxylin-eosin (H&E)-stained sections were assessed at the pathology departments of the participating hospitals by local pathologists for both series. In the RASTER series, two hospitals utilised the same pathology department; therefore, the original histopathological examination was carried out at 15 pathology departments. Histological tumour grade was determined according to the Elston and Ellis method [30] , and ER, PgR and HER2 status according to locally used methods.
According to Dutch guidelines, the ER and PgR were considered positive if at least 10% of tumour cells stained positive using an immunohistochemical assay [3] . Samples were deemed HER2 positive if the score was 3+ in immunohistochemical assay (defined as uniform intense membrane staining of >10% of invasive tumour cells) [3] . If the score was 2+ in immunohistochemical assay (defined as uniform membrane staining of >10% of invasive tumour cells with a moderate intensity of staining) and a FISH result or chromogenic in situ hybridisation (CISH) result was available, the FISH/CISH result (positive or negative) was used. For FISH, a ratio of HER2 to centromere chromosome 17 >2.0 was considered positive; for CISH, a result of more than five HER2 gene copies per nucleus was considered positive [3, 31] . If FISH/CISH was not available, a score of 2+ was considered negative for HER2. A score of 0 (defined as uniform intense membrane staining of <10% of invasive tumour cells) or 1+ (defined as weak uniform or partial membrane staining of >10% of invasive tumour cells) was always considered negative for HER2 [3] .
central histopathology review
For each tumour in the study, one paraffin block containing a representative part of the tumour was collected at The Netherlands Cancer Institute. An H&E-stained section was used to assess histological grade according to the Elston & Ellis method [30] , and ER, PgR and HER2 status (assessed by immunohistochemistry) were determined by three experienced breast pathologists (MJvdV, JLP and JW). In case of discordance between the original pathological examination and central review with regard to grade, the examination was carried out again by a panel of experienced breast pathologists who then agreed on a final grade. For the validation series, this panel consisted of MJvdV, JPL and JW and for the RASTER series, the panel consisted of MJvdV and JW. MJvdV carried out the central review in 75% (523 of 694) of the patients and JLP and JW in 12% (86 of 694) and 12% (85 of 694) of patients, respectively.
Immunohistochemical staining was carried out on 3-lm-thick paraffinembedded tumour sections after microwave antigen retrieval (citrate buffer, pH 6.0 for 15 min) using commercially available monoclonal mouse antibodies to ER (1D5+ 6F11, 1:200 dilution; NeoMarkers, LabVision, Fremont, CA), monoclonal mouse antibodies to PgR (PR-1, 1 : 400 dilution; ImmunoLogic, Duiven, The Netherlands) and monoclonal rabbit antibodies to HER2 (SP3 [32] , 1 : 3000 dilution; NeoMarkers, LabVision) and using the Power Vision detection kit (ImmunoLogic) and the Stainer Lab Vision 2D (LabVision).
For determination of ER, PgR and HER2 status, the same criteria were used as for the local assessment. However, in case of an HER2 2+ score in the absence of locally carried out FISH or CISH, CISH was carried out on 5-lm paraffin-embedded tumour sections. Sections were heated for 90 min at 75°C in an incubator, de-paraffinised in fresh xylene twice for 10 min each time, dehydrated in three changes of absolute ethanol for 5 min and airdried. Pretreatment, hybridisation and post-hybridisation washes were carried out according to the manufacturer's description using Zymed SpoTLightÒ HER2 CISHä Kit. If less than six copies per tumour cell were present, a tumour was considered HER2 negative; if six or more copies were present, a tumour was considered HER2 amplified [31] .
Patient and tumour characteristics of the local and centrally reviewed histopathological findings (N = 694) are summarised in [30] . Patients with a clinical high-risk tumour will benefit most from adjuvant systemic treatment (e.g. chemotherapy, endocrine therapy or both; Oxford Overview) and therefore, adjuvant systemic treatment is advised in these patients [33, 34] . The use of the Dutch 'CBO guidelines' has been described in detail by Bueno-de-Mesquita et al. [29] .
international adjuvant systemic treatment guidelines
International guidelines used in this study to assess the clinical risk and need for adjuvant systemic treatment were St Gallen guidelines [4] , NPI [5] [6] [7] [8] and Adjuvant! Online (www.adjuvantonline.com, version 8.0) [9, 10] . A moderate or high clinical risk was considered to be an indication for adjuvant systemic treatment.
For patients included in the validation series, the St Gallen guidelines published in 1998 [35] were used as described in Bueno-de-Mesquita et al. . of patients  694  122  17  572  83  Age, years  £35  44  6  12  10  32  6  ------36-40  68  10  10  8  58  10  ------41-45  130  19  20  16  110  19  ------46-50  225  32  40  33  185  32  ------51-55  183  26  40  33  143  25  ------>55  44  6  --44  8  ----- [4] . The NPI computes a score using the following algorithm: 0.2 · size (cm) + grade + nodal status [5] [6] [7] [8] .
The Adjuvant! Online software calculates a 10-year survival probability based on the patient's age, tumour size, histological tumour grade, ER status and nodal status. A low clinical risk was defined as patients with a 10-year survival probability of at least 90%. The application of the Adjuvant! Online software was in conformation with the use of this guideline as described in Bueno-de-Mesquita et al. [29] . The Adjuvant! Online software does not give an advice but returns risk estimates and the calculated benefits of adjuvant systemic treatment [9, 10] .
statistical analysis
Analyses were carried out using the statistical package SPSS [SPSS for Windows, Release 15.0.1. (22 November 2007) ; SPSS Inc., Chicago, IL]. The differences in patient and tumour characteristics between the two patient series were tested using the Pearson chi-square test. In case of ordinal variables (age, pT stage of tumour-node-metastasis, histological grade and nodal status) with more than two groups, we tested for trends (using Cochran-Armitage test). A significant finding was defined as a P value <0.05. The level of agreement between the original pathological examination and the central pathological review was expressed by means of a Cohen's kappa. Level of agreement between clinical risk assessment based on original pathological examination and central pathological review, and its impact on adjuvant systemic treatment advice, was also expressed by means of a Cohen's kappa. A kappa of one indicates perfect agreement, whereas a kappa of zero indicates no agreement. Table 2 ).
The discordance between the original pathological evaluation and the central review has been analysed for separate prognostic factors. Four per cent [21 of 564; 95% confidence interval (CI) 2% to 5%; According to St Gallen guidelines, 12% of patients (kappa 0.58) would have been given a different clinical risk and treatment advice after central review (7% high to low risk and 5% low to high risk; Table 3C ). Originally clinical low-risk (29%; 33 of 113; 95% CI 21% to 38%) tumours based on St Gallen guidelines were more sensitive to inter-observer variation than originally high risk (9%; 51 of 575; 95% CI 7% to 11%). Based on the NPI, 14% (95 of 689; missing 5) of patients (kappa 0.72) would have been given a different clinical risk and treatment advice after central review (7% originally high to low risk and 7% originally low to high risk; Table 3D ). Originally high-risk tumours based on the NPI were equally susceptible to inter-observer variation [16% (48 of 300); 95% CI 12% to 20%] as originally low-risk patients [12% (47 of 389); 95% CI 9% to 15%].
The impact of inter-observer variation for clinicopathological risk assessment was most apparent in histological grade compared with the other factors evaluated. Especially, grade 2 tumours were more sensitive to interobserver variation compared with grade 1 and 3 tumours as kappas differed substantially (Table 4) . The findings of our study show that inter-observer variation in pathological examination of breast carcinomas results in substantial differences in clinicopathological risk assessment and subsequently in adjuvant systemic treatment advice. Histologic tumour grading was most sensitive to inter-observer variation among pathologists. Central review changed the histologic tumour grade in 28% of patients. Especially, grade 2 tumours were susceptible (35%) to inter-observer variation. In other studies, the concordance between pathologists in assessing grade was found to range from 50% to 85%, which is in line with our results (72%) [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] .
Central review changed the clinical risk assessment and adjuvant systemic treatment advice of 102 of 689 patients (15% or approximately one in seven patients) if Dutch CBO guidelines (2004 version) were used. For 61 of these patients (9%), the central review resulted in a change from a high to a low risk and as a consequence, the treatment advice to undergo adjuvant systemic treatment would change into the advice not to undergo adjuvant systemic treatment. For 41 original article Annals of Oncology (6%) of the patients, adjuvant systemic treatment would have been advised after central review but was not advised based on the original evaluation. Clinical CBO low-risk tumours (based on local assessment) were less sensitive to inter-observer variation (11%; 1 in 10 patients) than high-risk tumours (19%; one in five patients). If Adjuvant! Online were used, clinical risk and adjuvant systemic treatment advice would change in 1 in 12 patients (8%). The discordance in clinical risk and treatment advice based on the St Gallen guidelines and NPI was in, respectively, 12% (one in eight) and 14% (one in seven) of patients. Dutch CBO guidelines, St Gallen guidelines and NPI were more sensitive to inter-observer variation than Adjuvant! Online indicating that tumour diameter and/or age are more heavily weighed for risk assessment by Adjuvant! Online than by other guidelines. It is of note that St Gallen low-risk tumours were most sensitive to inter-observer variation (29%; one in three patients) compared with St Gallen high-risk tumours (9%; 1 in 11 patients) and compared with other guidelines. This is probably due to the fact that grade 2 tumours are intermediate/high-risk tumours according to the St Gallen guidelines, while grade 2 tumours were more sensitive to interobserver variation than grade 1 or 3 tumours. The distribution of grade and frequency of ER-, PgR-and HER2-positive tumours was similar to that of other populations, indicating that patients included in this study were representative of the general breast cancer population.
We found a false-positive HER2 assessment in 21% of the cases, a number that is very similar to that reported in other series [24] . Paik et al. [24] postulated that a bias is introduced by local pathologists in small-volume laboratories who overestimate HER2 positivity and thereby may cause a high degree of discordance. This supports the importance of using a high-volume laboratory, experienced pathologists and rigorous application of standardised procedures for HER2 testing.
Paik et al. [19] studied the degree of agreement in the assignment of tumour grade among three pathologists as a prespecified secondary objective in a larger study in which they validated the prognostic 21-gene recurrence score. This 21-gene recurrence score quantifies the likelihood of distant recurrence in ER-positive node-negative tamoxifen-treated breast cancer. They observed that the concordance among pathologists for poorly differentiated tumours was moderate (kappa 0.61) and for well-differentiated and moderately differentiated grades was low (kappa 0.23 and 0.36, respectively). They concluded that a possible advantage of the recurrence score or comparable gene expression profiles over tumour grading in clinical practice is that it is less susceptible to inter-observer variability and therefore more reproducible.
The inter-observer variation was higher in grade 2 tumours than in grade 1 and 3 tumours; subsequently, the impact of inter-observer variation on clinicopathological risk assessment, regardless of what guideline was used, was higher in grade 2 tumours compared with grade 1 and 3 tumours. Gene expression analyses carried out by Sotiriou et al. [21] showed that gene expression in grade 2 tumours resembles that of grade 1 tumours in half of the cases and resembles gene expression of grade 3 tumours in the other half. This observation supports our conclusion that grade 2 tumours are a mixed tumour group and hard to reproducibly classify.
Viale et al. [22] reported the results of a central pathological review of the ER and PgR status in patients included in the BIG I-98 trial. In this trial, only postmenopausal women with ERand/or PgR-positive tumours were included. The central review confirmed 97% as ER positive and 82% as PgR positive, implying an inter-observer variation of 3% (95% CI 3% to 4%) and 18% (95% CI 17% to 19%) for a change in hormone receptor status from positive to negative. Our study is in line with these results as the inter-observer variation for ER assessment was 5% (95% CI 3% to 6%) for the change from positive to negative. The inter-observer variation for PgR assessment was lower in our study (12%; 95% CI 10% to 15%).
conclusion
We conclude that inter-observer variation in pathological examination of breast carcinomas results in considerable 
